

99.9% of the time, said Tosi.

Moreover, the electrically controlled qubits can communicate with each other at larger distances than can the qubits in other silicon designs. That bodes well for scaling up because the qubits can be far enough apart to allow room for control and read-out instruments to be placed between them. The atoms also do not need to be placed precisely, so they would fit with existing microprocessor-fabrication techniques, added Tosi.

Although Morello's team has demonstrated the high precision only in a single atom, the researchers have started to experiment with a two-atom system, and expect this level of performance to scale up. "From there, there are no basic first-principle barriers," said Tosi.

He has patented a design for a larger-scale computer and says that it should be possible to manufacture chips that use their system in plants similar to those already used to make present-day microprocessors.

SPIN CITY

Another silicon project from UNSW, led by physicist Andrew Dzurak, uses as its qubits the spins of electrons in a set-up that is based on modified electrical transistors. Although the qubits are less robust than those in the Morello design, Dzurak's team demonstrated two-qubit calculations last October.

At the London event, Tosi and Schmitt were grilled on the Morello team's plan. "It's a beautiful scheme," said John Morton, an electrical engineer at University College London. But he cautioned that aspects of the business model that the duo presented as part of the event seemed reliant on superconducting qubits not getting any better. "That's a risky thing to do," Morton said. Neven agreed, pointing out that silicon qubits will need to demonstrate advantages in other areas if they are to get a foothold in the future quantum-computer market.

Like superconducting qubits, silicon qubits must be kept at a fraction of a degree above absolute zero. Morton said that the Morello design's big advantage is that the qubits are atomic scale. In principle, that would allow many more to be placed on each chip than is possible with superconducting qubits, which are around 100 micrometres across. To seize this opportunity, the design needs to shed the bulky microwave devices that it proposes as its means to operate between distant qubits, said Neven.

The successes of the Australian quantum centre — which is led by UNSW physicist Michelle Simmons — are partly down to its wider expertise in nanoscale silicon fabrication, says Peter Knight, a physicist at Imperial College London and a panel member at the event. When it comes to fabrication, he says, the centre is way ahead of others working in silicon. ■

CANCER SCREENING

Myriad Genetics caught in data fight

Complaint to US government alleges that company violated people's right to access health information.

BY ERIKA CHECK HAYDEN

Genetic-testing firm Myriad Genetics is facing a legal challenge from people who say the company refused to give them access to their own genomic data, in violation of a US government rule on medical records.

Although Myriad has now agreed to release the data to those individuals, the patients are pressing ahead with their complaint to the US government. The skirmish is the latest in a long-running war between Myriad and data-sharing advocates, and it could ultimately force the company to provide genetic information that patients could then share with scientists.

The patients, who are represented by the American Civil Liberties Union (ACLU), filed the complaint on 19 May with the US government alleging that Myriad, of Salt Lake City, Utah, had declined to release complete results of tests for the genes *BRCA1* and *BRCA2*. Some variants of these genes are linked to higher risk of cancer; for others, the link to disease is unclear or the variants are considered to be harmless.

Myriad refused to report 'benign' *BRCA* variants back to patients when they requested this information in February. The ACLU says that the company's denial violates a rule released by the US government in January that gives patients the right to obtain their full lab test results under the Health Insurance Portability and Accountability Act.

TOTAL ACCESS

Breast-cancer survivor AnneMarie Ciccarella, one of the people who filed the complaint, said that she wants access to her complete data so that she can share it with scientists who are trying to understand the genetic contributions to cancer. "I want to see that the research community has access to every bit of data that has been generated from my body," she said.

On 18 May, after the ACLU announced a press conference to discuss the complaint, Myriad released the data that Ciccarella and her three co-complainants had requested. "We believe the complaint lacks merit and should not be accepted," the company said in a 19 May statement.

Ciccarella and the others who brought the

complaint are pressing ahead with their case, in part to set the precedent that companies must legally provide the full results of genetic tests — not release it on a voluntary basis.

Observers say that makes sense, especially given Myriad's history. The company had previously tried to block rivals from providing *BRCA* tests, asserting that it held patents that gave it the exclusive right to perform such diagnostics.

That changed in June 2013, when the US Supreme Court invalidated Myriad's patents after the ACLU mounted a legal challenge. Myriad has not shared its large database on thousands of *BRCA* variants, despite requests from researchers studying the genetics of breast cancer. But it may now be forced to provide

"I want to see that the research community has access to every bit of data that has been generated from my body."

individual results on a patient-by-patient basis if the government decides to accept the latest complaint.

"If I were the plaintiffs, I'd want to make sure the government said that Myriad had to do what it did," says lawyer and bioethicist Hank Greely at Stanford University in California. "If you're a consumer advocate in the health-care space, Myriad may not be a company you trust."

Heidi Rehm, a geneticist at the non-profit company Partners Healthcare Personalized Medicine in Cambridge, Massachusetts, drafted a statement of support for the complaint against Myriad. She says that as researchers learn more about genetic risks of cancer, they're finding that variants once considered benign might actually contribute to cancer risk.

Rehm and other researchers are pushing for companies and individuals to share their genetic test data with open databases such as ClinVar, and she says that the push for data sharing is gathering increasing momentum. US insurance company Aetna, for instance, has said that it will favour testing companies that deposit data in ClinVar. And the US Food and Drug Administration is considering whether to give companies incentives to deposit their tests results in the database. ■

Additional reporting by Heidi Ledford.